SynthesisHepatology international2020
Incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients: a systematic review and meta-analysis.
Synthesis in Hepatology international, 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 73 papers, 4 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
73 citing papers in PubMed, 4 syntheses or guidelines pooled it.
- Liver Injury in COVID-19 Patients with Drugs as Causatives: A Systematic Review of 996 DILI Cases Published 2020/2021 Based on RUCAM as Causality Assessment Method.International journal of molecular sciences · 2022Pooled it
- A systematic review and meta-analysis of regional risk factors for critical outcomes of COVID-19 during early phase of the pandemic.Scientific reports · 2021Pooled it
- COVID-19 gastrointestinal manifestations: a systematic review.Revista da Sociedade Brasileira de Medicina Tropical · 2020Pooled it
- Clinical features and corresponding immune function status of recurrent viral polymerase chain reaction positivity in patients with COVID-19 : A meta- analysis and systematic review.International journal of immunopathology and pharmacologyPooled it
- Gastrointestinal Symptoms and Abnormal Liver Biochemistry in Patients with COVID-19 Pneumonia Admitted to the Department of Gastroenterology After Ending Zero-COVID Policy in China.Advances in therapy · 2026Article
- Biomarkers of Multiorgan Failure in COVID-19: A Predictive Framework for Disease Severity and Clinical Outcomes.Saudi medical journal · 2026Article
- Gene signatures and networks: linking COVID-19 to liver cirrhosis and hepatocellular carcinoma.BMC infectious diseases · 2025Article
- Article
- Elevated non-invasive liver fibrosis scores at admission are independent risk factors for severe COVID-19: a retrospective cohort study from 2020 to 2024.Frontiers in medicine · 2025Article
- Indeterminate Result of Interferon-γ Release Assay-A Risk Factor of Mortality for COVID-19 and Non-COVID-19 Respiratory Infections.Journal of medical virology · 2024Article
- Spectrum of COVID-19 induced liver injury: A review report.World journal of hepatology · 2024Review
- Review
- Nirmatrelvir/ritonavir or Molnupiravir for treatment of non-hospitalized patients with COVID-19 at risk of disease progression.PloS one · 2024Article
- Association between acute liver injury & severity and mortality of COVID-19 patients: A systematic review and meta-analysis.Heliyon · 2023Article
- Liver Function in Patients with Long-Term Coronavirus Disease 2019 of up to 20 Months: A Cross-Sectional Study.International journal of environmental research and public health · 2023Article
- Outcomes of COVID-19 among patients with liver disease.World journal of gastroenterology · 2023Review
- COVID-19 and liver injury: An ongoing challenge.World journal of gastroenterology · 2023Review
- Serum metabolomics strategy for investigating the hepatotoxicity induced by different exposure times and doses ofRSC advances · 2023Article
- Liver pathology in COVID-19 related death and leading role of autopsy in the pandemic.World journal of gastroenterology · 2023Review
- COVID-19: Has the Liver Been Spared?International journal of molecular sciences · 2023Review
13 more citing papers are in PubMed but not listed here.
Corrections and comments
- Commented on byREPLY.2021
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
BACKGROUND AND
aimsCoronavirus disease 2019 (COVID-19) pandemic is ongoing. Except for lung injury, it is possible that COVID-19 patients develop liver injury. Thus, we conducted a systematic review and meta-analysis to explore the incidence, risk factors, and prognosis of abnormal liver biochemical tests in COVID-19 patients.
methodsPubMed, Embase, Cochrane Library, China National Knowledge Infrastructure (CNKI), VIP, and Wanfang databases were searched. The incidence of abnormal liver biochemical tests, including aspartate aminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (ALP), gamma-glutamyl transpeptidase (GGT), total bilirubin (TBIL), and albumin (ALB), was pooled. Risk ratio (RR) was calculated to explore the association of abnormal liver biochemical tests with severity and prognosis of COVID-19 patients.
resultsForty-five studies were included. The pooled incidence of any abnormal liver biochemical indicator at admission and during hospitalization was 27.2% and 36%, respectively. Among the abnormal liver biochemical indicators observed at admission, abnormal ALB was the most common, followed by GGT, AST, ALT, TBIL, and ALP (39.8%, 35.8%, 21.8%, 20.4%, 8.8%, and 4.7%). Among the abnormal liver biochemical indicators observed during hospitalization, abnormal ALT was more common than AST and TBIL (38.4%, 28.1%, and 23.2%). Severe and/or critical patients had a significantly higher pooled incidence of abnormal liver biochemical indicators at admission than mild and/or moderate patients. Non-survivors had a significantly higher incidence of abnormal liver biochemical indicators than survivors (RR = 1.34, p = 0.04).
conclusionsAbnormal liver biochemical tests are common in COVID-19 patients. Liver biochemical indicators are closely related to the severity and prognosis of COVID-19 patients.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.